Indivior Pharmaceuticals Inc
INDV
Company Profile
Business description
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Contact
10710 Midlothian Turnpike
Suite 125
North Chesterfield
RichmondVA23235
USAT: +1 804 379-1040
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
838
Stocks News & Analysis
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
All that glitters is not gold.
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
Shoppers are being hit by double whammy of oil and rising rates.
stocks
ASX data center player sells US assets to bolster balance sheet
Asset sale in response to growing investor concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,107.00 | 36.90 | 0.41% |
| CAC 40 | 8,202.08 | 97.34 | -1.17% |
| DAX 40 | 24,663.61 | 255.08 | -1.02% |
| Dow JONES (US) | 49,744.86 | 165.73 | -0.33% |
| FTSE 100 | 10,276.95 | 161.71 | -1.55% |
| HKSE | 26,626.28 | 412.50 | 1.57% |
| NASDAQ | 25,883.22 | 44.27 | 0.17% |
| Nikkei 225 | 62,833.84 | 3,320.72 | 5.58% |
| NZX 50 Index | 13,270.61 | 125.42 | 0.95% |
| S&P 500 | 7,358.83 | 6.29 | -0.09% |
| S&P/ASX 200 | 8,878.10 | 32.70 | 0.37% |
| SSE Composite Index | 4,180.09 | 19.92 | 0.48% |